We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wylie you're spot on but seems like on AIM everyone wants millions yesterday, so many impatient investors. When you step back what AVCT have achieved in 12 months is nothing short of monumental yet all you hear is "still no test".....
The good thing at this SP is basically nobody is underwater so its fine to say, if you don't like the way the company is operating, sell up and go somewhere else, it wont cost you anything. They wont though because the FOMO is too much....
Too many armchair CEOs
jdt; the improvements to the test would be in response to the mutating virus. A narrow remit with covid can only be applied for the pandemic on a particular day and even that will be late. Affimers appear to be the quickest way to respond to mutations. A test can only be measured in use and the government thinks Innova is pretty good as does Mina but I think ours would be better for curbing spread in a test for back to normality in society (plus regular test) scenario.
Lockdowns are not an option and a whole year of affimer tests has been wasted imo.
Why don't people remember that this is an opportunity for Avacta to make some nice cash from Covid, but Avacta does not exist BECAUSE of Covid. It exists as an innovative treatment for cancer!!
If you don't like their strategy then they're not going to loose sleep over it - unlike some on here..
TWAT
Would be nice if Sir Al gets his tests out before everyones died of Covid just saying...... getting beyond a joke surely!
Or is Sir Al rehearsing for Carry On Testing!!
I get your point on the widespread use of Affimers. But "just get a test out there isn't" the way to do it. If this last 8 months or so has shown anything, it's that goalposts shift. To be in a position where we have a LFT framework that is plug and play for Affimers future proofs against any tinkering, which takes time, may require adjustments to manufacturing processes etc.
Your route would inevitable lead to multiple trips back to the drawing board and tweaking the process. Wholly counterproductive.
jdt; that unfortunately is a failed procedure. It is precisely because I want to see affimers applied in myriad directions that the most simple of measures has to prove how good they are so get a test out there.
Slinky! That's the nicest thing you have ever said about me....
Doze - what you're suggesting is all well and good when you are just a middle man like Innova. They have no brand, IP, reputation to protect. This was a very good smash and grab from them.
AVCT is Affimers not LFT's. Affimers (as I am sure you have seen from the various non Covid RNS's the last 4 months) have applications far and wide outside covid.
"Speed is of the essence with this virus so address the imperative not the regulators narrow remit and then in the market you have a test you keep tweeking to improve it."
Not in AVCT's case, they have to do it right and make sure what they produce can't be trashed by the likes of Deeks because once AVCT's name is on it, it's the reputation of the IP that's on the line. AVCT want to be a part of a wider UK diagnostics industry post Covid. You sure as hell wont see Innova in the mixer for that job....
wherever AS
Affimers are specific and early to detect so a test out there will prove that point. Preferably saliva, wherever As can get it on the market. Speed is of the essence with this virus so address the imperative not the regulators narrow remit and then in the market you have a test you keep tweeking to improve it. The government have been bending the rules for CE marked tests so trained staff can oversee.
Interesting innova have done it the right way an "American" company the Americans won't touch. In fact is it just the UK gov who use them ? What was used to screen the whole populations in Scandinavia?
"The right strategy would have been to get an antigen spike test on the market and selling with the data collected as per Innova for a straight head to head"
Come off it Doze - AS wont be worrying about you taking his job ever. Why the hell would AVCT want to be embroiled in a head to head with Innova, thats the last bit of press Affimers would need, think of the knock on reputational consequences.
What AVCT need to do is blow Innova out of the water so they never see the light of day again and AVCT show what LFT's can do, as a result of including Affimers.
"The proof is in the pudding not the regulators lab" - Yes and that is why AS had done a larger CV using clinical samples with an AN test. That will most likely reduce the disparity between clinical S&S and real world S&S. So that is exactly what they are trying to do here.
Doze...if they want to sell into Europe they need it...at this point we don't know what deals they are negotiating outside UK Govt tender...
The right strategy would have been to get an antigen spike test on the market and selling with the data collected as per innova for a straight head to head. The proof is in the pudding not the regulators lab. Apparently it is the easiest thing to do unless you are AS. It does not matter about the S and S just what the test does in use. I believe in the affimer if it ever sees the light of day.